Synonyms: IMP-4297 | IMP4297
Compound class:
Synthetic organic
Comment: Senaparib (IMP4297) is an oral poly(ADP-ribose) polymerase 1 (PARP1) inhibitor [1] that is being developed in a joint venture between IMPACT Therapeutics and Junshi Biosciences, for the treatment of BRCA-mutated solid tumours. It is one of the chemical structures claimed in patent WO2012130166A1 [2].
|
|
Bioactivity Comments |
Senaparib potently kills tumour cells with BRCA1/2 mutations in vitro, and it is efficacious in BRCA1/2 mutant tumour xenograft models [1]. |